Subscribe
Washington -- In the treatment of moderate-to-severe atopic dermatitis, pimecrolimus (Elidel) cream 1 percent is less likely than tacrolimus (Protopic) ointment 0.1 percent to be systemically absorbed, according to Zoe Draelos, M.D., lead investigator of a blind treatment trial that compared systemic exposure levels of the two topical drugs.
Sun exposure's role in melanoma backed by studies
Control of pruritus pushes pimecrolimus
Bioengineered skin improves pediatric wound healing
Clinical judgement still key
Joseph Gorelick, MSN, FNP-C
Brad P. Glick, DO, MPH, FAAD
Hilary Baldwin; Neal Bhatia, MD
Tina Bhutani, MD
June 17-19, 2026
Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD
Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc
Andrew Alexis, MD, MPH; Leon Kircik, MD
Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD
Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD